CVS

CVS Health Corp. Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026, and the six months ended on that date. CVS Health operates as an integrated health solutions company with four reportable segments: Health Care Benefits (Aetna), Health Services (CVS Caremark), Pharmacy & Consumer Wellness (Retail), and Corporate/Other. As of June 30, 2026, the company operated approximately 9,000 retail locations and served approximately 87 million PBM plan members and 37 million health insurance members.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 7.3% in Q2 and 6.7% in the first six months of 2026 compared to the prior year, driven by growth across all segments.
• Profitability Surge: Operating income increased 97.5% in Q2 and 63.0% for the six-month period. This significant improvement is primarily attributed to the absence of $833 million in legacy litigation charges and $288 million in losses on Accountable Care assets that were recorded in the prior year.
• Segment Performance:
  • Health Care Benefits: Adjusted operating income rose 85.5% in Q2, driven by improved Government business performance and the absence of prior-year premium deficiency reserves.
  • Health Services: Revenues grew 11.5% in Q2 due to pharmacy drug mix and brand inflation, partially offset by client price improvements.
  • Pharmacy & Consumer Wellness: Operating income increased 91.7% in Q2, aided by the absence of legacy litigation charges and contributions from Rite Aid asset acquisitions.
• Cost Management: Operating expenses decreased 1.5% in Q2 and 1.1% for the six months, largely due to the lack of prior-year litigation and restructuring charges.

Outlook, Risks, and Contingencies

• Regulatory Environment: The company faces ongoing investigations and litigation regarding PBM practices, including a proposed settlement with the FTC announced in July 2026 to resolve outstanding investigations. Legislation regulating PBM activities is active in many states.
• Legal Contingencies:
  • Opioid Litigation: As of June 30, 2026, the remaining accrual for opioid-related litigation matters was approximately $3.4 billion.
  • Omnicare Litigation: A liability of $165 million remains on the balance sheet related to joint and several liability for penalties in a False Claims Act case involving Omnicare, pending bankruptcy court approval of a settlement.
• Capital Allocation: The company did not repurchase any shares during the six months ended June 30, 2026. The quarterly dividend remained at $0.665 per share. Approximately $11.5 billion remains available under authorized share repurchase programs.
• Trends: Management notes elevated utilization levels in Q2 2026 and continued pressure from pharmaceutical manufacturers regarding rebate calculations. The company expects these trends to persist.

Investor Verification Checklist

• Quality of Earnings: Verify the extent to which the reported profit growth is driven by the absence of one-time litigation charges ($833M in Q2 2025) versus organic operational improvements.
• Legal Exposure: Monitor the status of the $3.4 billion opioid litigation accrual and the finalization of the FTC settlement and Omnicare bankruptcy proceedings.
• Regulatory Impact: Assess the potential financial impact of state and federal PBM regulations and the outcome of the FTC settlement on future pricing models.
• Membership Trends: Review the decline in Commercial medical membership (down 19.7% in Q2) versus growth in Government membership to understand the shifting risk profile of the Health Care Benefits segment.
• Cash Flow Sustainability: Confirm that the 64.2% increase in operating cash flow is sustainable given the timing of payments and receipts noted by management.